Compare · NVO vs ZSTK
NVO vs ZSTK
Side-by-side comparison of Novo Nordisk A/S (NVO) and ZeroStack Corp. (ZSTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZSTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 16371.5x ZSTK ($11.7M).
- Over the past year, NVO is down 45.7% and ZSTK is down 78.2% - NVO leads by 32.5 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for ZSTK).
- NVO has more recent analyst coverage (25 ratings vs 0 for ZSTK).
- Company
- Novo Nordisk A/S
- ZeroStack Corp.
- Price
- $41.01-4.51%
- $5.20+17.12%
- Market cap
- $191.82B
- $11.7M
- 1M return
- -10.44%
- -28.96%
- 1Y return
- -45.66%
- -78.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 1
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest ZSTK
- SEC Form PRER14A filed by ZeroStack Corp.
- SEC Form PRE 14A filed by ZeroStack Corp.
- SEC Form 4 filed by Director Zeifman Laurence
- SEC Form 4 filed by Director Woo Edward
- SEC Form 4 filed by Director Leventhal Manfred
- ZeroStack Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by ZeroStack Corp.
- SEC Form 4 filed by Heinrich Michael
- Nasdaq-Listed ZeroStack Corp. Makes $107 Million Institutional Commitment To Increase Strategic Position in 0G Token Ecosystem
- ZeroStack Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits